var data={"title":"Cefuroxime: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefuroxime: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5849?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefuroxime-drug-information\" class=\"drug drug_general\">see &quot;Cefuroxime: Drug information&quot;</a> and <a href=\"topic.htm?path=cefuroxime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefuroxime: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148304\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ceftin;</li>\n      <li>Zinacef in Sterile Water [DSC];</li>\n      <li>Zinacef [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148305\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cefuroxime;</li>\n      <li>Auro-Cefuroxime;</li>\n      <li>Ceftin;</li>\n      <li>Cefuroxime For Injection;</li>\n      <li>Cefuroxime For Injection, USP;</li>\n      <li>PRO-Cefuroxime;</li>\n      <li>ratio-Cefuroxime</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046145\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Second Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442230\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b> IM, IV (<i>Red Book</i> [AAP 2015]):</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Body Weight</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postnatal Age</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 to 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 to 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046138\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefuroxime-drug-information\" class=\"drug drug_general\">see &quot;Cefuroxime: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 20 to 30 mg/kg/day divided twice daily; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM, IV: 75 to 100 mg/kg/day divided in 3 doses; maximum dose: 1,500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: IM, IV: 100 to 200 mg/kg/day divided in 3 to 4 doses; maximum dose: 1,500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone and joint infection:</b> Infants &ge;3 months, Children, and Adolescents: IM, IV: 50 mg/kg/dose every 8 hours; maximum dose: 1,500 mg/dose. <b>Note: </b>Upon completion of parenteral therapy follow with oral antibiotic therapy if indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bronchitis, chronic; acute exacerbations:</b> Adolescents: Oral tablets: 250 to 500 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Impetigo:</b> Infants &ge;3 months and Children: Oral suspension: 15 mg/kg/dose twice daily for 10 days; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection complicated, community-acquired:</b> Infants, Children, and Adolescents: IV: 150 mg/kg/day in divided doses every 6 to 8 hours; maximum dose: 1,500 mg/dose (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acrodermatitis chronica atrophicans: Oral: 15 mg/kg/dose every 12 hours for 21 days; maximum dose: 500 mg/dose (Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Early localized disease: Oral: 15 mg/kg/dose every 12 hours for 14 days; maximum dose: 500 mg/dose (<i>Red Book</i> [AAP 2015]; Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Late disease (arthritis): Oral: 15 mg/kg/dose every 12 hours for 28 days; maximum dose: 500 mg/dose (Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute:</b> Infants &ge;3 months and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral suspension: 15 mg/kg/dose twice daily for 10 days; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral tablet (patients able to swallow tablet whole): 250 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note</b>: AAP recommends variable duration of therapy depending on age: If 6 months to 2 years of age or severe symptoms (any age): 10-day course; if 2 to 5 years of age with mild to moderate symptoms: 7-day course; if &ge;6 years of age with mild to moderate symptoms: 5- to 7-day course (AAP [Lieberthal 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/tonsillitis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children: Oral suspension: 10 mg/kg/dose twice daily for 10 days; maximum dose: 250 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral tablets: 250 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, bacterial (HIV-exposed/-positive):</b> Infants and Children: IV: 35 to 50 mg/kg/dose 3 times daily; maximum dose: 2,000 mg/dose (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sinusitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral suspension: 15 mg/kg/dose twice daily for 10 days; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral tablet (for patients able to swallow tablet whole): 250 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral tablet: 250 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections, uncomplicated:</b> Adolescents: Oral tablet: 250 to 500 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 50 mg/kg within 60 minutes prior to procedure; may repeat dose in 4 hours if procedure is lengthy or if there is excessive blood loss; maximum dose: 1,500 mg/dose (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection, uncomplicated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 2 to 24 months: Oral suspension: 10 to 15 mg/kg/dose twice daily (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;24 months: Moderate to severe disease (possible pyelonephritis): Oral suspension: 20 to 30 mg/kg/day divided twice daily; maximum dose: 500 mg/dose (Bradley 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral tablet: 250 mg twice daily for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bronchitis, chronic; acute exacerbations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 250 to 500 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 500 to 750 mg every 8 hours (complete therapy with oral dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cholecystitis, mild to moderate:</b> IV: 1,500 mg every 8 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated, community-acquired, mild to moderate (in combination with metronidazole):</b> IV: 1,500 mg every 8 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease (early):</b> Oral: 500 mg twice daily for 20 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/tonsillitis and sinusitis:</b> Oral: 250 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, uncomplicated:</b> IM, IV: 750 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe or complicated infections:</b> IV: 1,500 mg every 8 hours (up to 1,500 mg every 6 hours in life-threatening infections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin/skin structure infection, uncomplicated: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 250 to 500 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 750 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's recommendation: IV: 1,500 mg 30 minutes to 1 hour prior to procedure (if procedure is prolonged can give 750 mg every 8 hours IV or IM)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Open heart: IV: 1,500 mg every 12 hours for a total of 4 doses starting at anesthesia induction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternative recommendation: IV: 1,500 mg within 60 minutes prior to surgical incision. Doses may be repeated in 4 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection, uncomplicated: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 250 mg twice daily for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, IM: 750 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been reported in the literature (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 30 mg/kg/day divided every 12 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 15 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: Administer 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): Administer 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: The manufacturer's labeling recommends decreasing the frequency similar to adult recommendations. The following guidelines have been used by some clinicians (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 75 to 150 mg/kg/day divided every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 25 to 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 25 to 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: Administer 25 to 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): Administer 25 to 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 25 to 50 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to &lt;30 mL/minute: Administer recommended dose based on indication every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer recommended dose based on indication every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD requiring intermittent hemodialysis (IHD): Additional recommended dose based on indication should be given at the end of each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;20 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 20 mL/minute: Administer recommended dose based on indication every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer recommended dose based on indication every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Administer additional recommended dose based on indication at the end of dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148279\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinacef in Sterile Water: 1.5 g (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravitreal, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL in NaCl 0.9% (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinacef: 750 mg (1 ea [DSC]); 1.5 g (1 ea [DSC]); 7.5 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 750 mg (1 ea); 1.5 g (1 ea); 7.5 g (1 ea); 75 g (1 ea [DSC]); 225 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinacef: 750 mg (1 ea [DSC]); 1.5 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 750 mg (1 ea [DSC]); 1.5 g (1 ea); 7.5 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as axetil [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceftin: 125 mg/5 mL (100 mL); 250 mg/5 mL (50 mL [DSC], 100 mL) [contains aspartame; tutti-frutti flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as axetil [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceftin: 250 mg [DSC], 500 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148263\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046149\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Cefuroxime axetil suspension must be administered with food; shake suspension well before use; tablets may be administered with or without food; administer with food to decrease GI upset; avoid crushing the tablet due to its bitter taste</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Inject deep IM into large muscle mass, such as gluteus or lateral part of thigh</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion: Administer over 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IVP: Administer over 3 to 5 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5193891\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store intact vials at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light. Reconstituted solution is stable for 24 hours at room temperature and 48 hours when refrigerated. IV infusion in NS or D<sub>5</sub>W solution is stable for 24 hours at room temperature, 7 days when refrigerated, or 26 weeks when frozen. After freezing, thawed solution is stable for 24 hours at room temperature or 21 days when refrigerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duplex container: Store unactivated units at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Unactivated units with foil strip removed from the drug chamber must be protected from light and used within 7 days. Once activated, may be stored for up to 24 hours at room temperature or for 7 days under refrigeration. Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TwistVial vials: Joined, but not activated, vials are stable for 14 days. Once activated, stable for 24 hours at room temperature and 7 days refrigerated. Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premix Galaxy plastic containers: Store frozen at -20&deg;C. Thaw container at room temperature or under refrigeration; do not force thaw. Thawed solution is stable for 24 hours at room temperature and 28 days refrigerated; do not refreeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Prior to reconstitution, store at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F). Reconstituted suspension is stable for 10 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046148\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Treatment of mild to moderate susceptible infections including pharyngitis/tonsillitis, acute bacterial maxillary sinusitis, acute bacterial otitis media, and impetigo (All indications: FDA approved in ages 3 months to 12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet: Treatment of mild to moderate susceptible infections including acute bacterial otitis media (FDA approved in pediatric patients [age not specified] and adults), acute bacterial maxillary sinusitis (FDA approved in pediatric patients [age not specified] and adults), acute bacterial exacerbations of chronic bronchitis (FDA approved in ages &ge;13 years and adults); pharyngitis/tonsillitis (FDA approved in ages &ge;13 years and adults); urinary tract (uncomplicated) (FDA approved in ages &ge;13 years and adults), skin and soft tissue (uncomplicated) (FDA approved in ages &ge;13 years and adults), urethral and endocervical gonorrhea (uncomplicated) (FDA approved in ages &ge;13 years and adults), and early Lyme disease (FDA approved in ages &ge;13 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment susceptible infections involving the lower respiratory tract, urinary tract, skin and skin structure, sepsis, uncomplicated and disseminated gonorrhea, and bone and joints (FDA approved in ages &ge;3 months and adults); meningitis (FDA approved in pediatric patients &ge;3 months); surgical prophylaxis (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Although FDA approved for the treatment of meningitis in pediatric patients and uncomplicated and disseminated gonococcal infections in adolescents and adults, cefuroxime is no longer recommended for these indications. In pediatric clinical trials, the use of cefuroxime has been found to be inferior to third-generation cephalosporins (eg, ceftriaxone) in the treatment of bacterial meningitis. Therefore, cefuroxime is NOT recommended for the treatment of bacterial meningitis (IDSA [Tunkel 2004]). Due to widespread resistance, cefuroxime should NOT be used for treatment of gonorrhea (CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148361\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefuroxime may be confused with cefotaxime, cefprozil, deferoxamine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceftin may be confused with Cefzil, Cipro</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinacef may be confused with Zithromax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ceftin [US, Canada] may be confused with Cefiton brand name for cefixime [Portugal]; Ceftim brand name for ceftazidime [Portugal]; Ceftime brand name for ceftazidime [Thailand]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148358\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Local thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaper rash (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea (duration-dependent), nausea and vomiting, unpleasant taste</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic: Decreased hematocrit, decreased hemoglobin, eosinophilia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Jarisch-Herxheimer reaction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, angioedema, anorexia, brain disease, candidiasis, chest tightness, cholestasis, <i>Clostridium difficile</i> associated diarrhea, colitis, decreased creatinine clearance, drug fever, dyspepsia, dysuria, erythema, erythema multiforme, gastrointestinal hemorrhage, gastrointestinal infection, glossitis, headache, hearing loss, hemolytic anemia, hepatitis, hyperactivity, hyperbilirubinemia, hypersensitivity, hypersensitivity angiitis, increased blood urea nitrogen, increased liver enzymes, increased serum creatinine, increased thirst, interstitial nephritis, irritability, joint swelling, leukopenia, muscle cramps, muscle rigidity, muscle spasm (neck), neutropenia, oral mucosa ulcer, pancytopenia, positive direct Coombs test, prolonged prothrombin time, pseudomembranous colitis, renal insufficiency, renal pain, seizure, serum sickness-like reaction, sialorrhea, sinusitis, Stevens-Johnson syndrome, swollen tongue, tachycardia, thrombocytopenia (rare), toxic epidermal necrolysis, trismus, upper respiratory tract infection, urethral bleeding, urethral pain, urinary tract infection, vaginal discharge, vaginal irritation, viral infection, vulvovaginal candidiasis, vulvovaginal pruritus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148286\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefuroxime, any component of the formulation, or other beta-lactam antibacterial drugs (eg, penicillins and cephalosporins)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148267\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam drugs. Before initiating therapy, carefully investigate previous penicillin, cephalosporin, or other allergen hypersensitivity. Use caution if given to a patient with a penicillin or other beta-lactam allergy because cross sensitivity among beta-lactam antibacterial drugs has been established. If an allergic reaction occurs, discontinue and institute appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; cephalosporins have been associated with seizure activity, particularly in patients with renal impairment not receiving dose adjustments. Discontinue if seizures occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suspension/tablet bioequivalence: Tablets and oral suspension are not bioequivalent; do not substitute on a mg-per-mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablets:  Should not be crushed or chewed due to a strong, persistent bitter taste.  Patients unable to swallow whole tablets should be prescribed the oral suspension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298999\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148272\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13137&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Cefuroxime. Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the absorption of Cefuroxime.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148300\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Bioavailability is increased with food; cefuroxime serum levels may be increased if taken with food or dairy products. Clinical and bacteriologic responses were independent of food intake in clinical trials. Management: Administer tablet without regard to meals; suspension must be administered with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148275\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5193889\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Cefuroxime crosses the placenta and reaches the cord serum and amniotic fluid. Placental transfer is decreased in the presence of oligohydramnios. Several studies have failed to identify an increased teratogenic risk to the fetus following maternal cefuroxime use.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">During pregnancy, mean plasma concentrations of cefuroxime are 50% lower, the AUC is 25% lower, and the plasma half-life is shorter than nonpregnant values. At term, plasma half-life is similar to nonpregnant values and peak maternal concentrations after IM administration are slightly decreased. Pregnancy does not alter the volume of distribution. Cefuroxime is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046144\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; number and type of stools/day for diarrhea; and prothrombin time. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148266\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148285\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral tablet: Increases with food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely to body tissues and fluids including bronchial secretions, synovial and pericardial fluid, kidneys, heart, liver, bone and bile; crosses blood-brain barrier; therapeutic concentrations achieved in CSF even when meninges are not inflamed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 33% to 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Cefuroxime axetil (oral) is hydrolyzed in the intestinal mucosa and blood to cefuroxime </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Tablet: Fasting: 37%; Following food: 52%; cefuroxime axetil suspension is less bioavailable than the tablet (91% of the AUC for tablets)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Premature neonates: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &le;3 days: Median: 5.8 hours (de Louvois 1982) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &ge;8 days: Median: 1.6-3.8 hours (de Louvois 1982) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents: 1.4-1.9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~1 to 2 hours; prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: ~15 to 60 minutes; IV: 2 to 3 minutes; Oral: Children: ~3 to 4 hours; Adults: ~2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (66% to 100% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148288\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cefuroxime Sodium-NaCl (PF) Intravitreal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL 0.9% (1 mL): $41.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefuroxime Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 g (1): $5.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 g (1): $23.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (1): $2.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefuroxime Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 g (1): $6.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Ceftin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (100 mL): $174.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (100 mL): $296.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cefuroxime Axetil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (20): $87.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (20): $160.31</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148291\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actixim (VN);</li>\n      <li>Adrox (BD);</li>\n      <li>Alporin (KR);</li>\n      <li>Altacef (PH);</li>\n      <li>Altamax (PH);</li>\n      <li>Anbacim (ID);</li>\n      <li>Aprok (IE);</li>\n      <li>Aprokam (GB);</li>\n      <li>Axet (PH);</li>\n      <li>Axetine (CN, NZ, PH, SG);</li>\n      <li>Axim (BD, HK);</li>\n      <li>Axurocef (TW);</li>\n      <li>Bacticef (IN);</li>\n      <li>C-Tri T (TH);</li>\n      <li>Carvixime (PH);</li>\n      <li>Cef2 (TZ);</li>\n      <li>Cefabiot (MX);</li>\n      <li>Cefasun (IN);</li>\n      <li>Cefero (LK);</li>\n      <li>Ceflour (MY);</li>\n      <li>Cefmono (PH);</li>\n      <li>Cefosan (PH);</li>\n      <li>Ceftil (KR);</li>\n      <li>Cefudura (DE);</li>\n      <li>Cefuhexal (DE);</li>\n      <li>Cefumax (LB, PH);</li>\n      <li>Cefuracet (MX);</li>\n      <li>Cefurax (DE);</li>\n      <li>Cefuro-Puren (DE);</li>\n      <li>Cefurox (TH);</li>\n      <li>Cefurox-wolff (DE);</li>\n      <li>Cefutil (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Cefutin (KR);</li>\n      <li>Cefuxime (HK, KR);</li>\n      <li>Cefxin (SG);</li>\n      <li>Cefzime (PH);</li>\n      <li>Celocid (ID);</li>\n      <li>Ceprosim (KR);</li>\n      <li>Cerox A (BD);</li>\n      <li>Ceroxim (IL, ZA);</li>\n      <li>Cethixim (ID);</li>\n      <li>Cetil (ET, IN, PE);</li>\n      <li>Cetoxil (MX);</li>\n      <li>Cexil (KR);</li>\n      <li>Cexim (HU);</li>\n      <li>CMaxid (HK);</li>\n      <li>Cortum (PH);</li>\n      <li>Curocef (AT, CL);</li>\n      <li>Curoxime (PT);</li>\n      <li>Daliroxim (LK);</li>\n      <li>Daroxime (LB, QA);</li>\n      <li>Deltrox (AR);</li>\n      <li>Efox (HR);</li>\n      <li>Efurox (MY);</li>\n      <li>Elobact (DE);</li>\n      <li>Eroxmit (PH);</li>\n      <li>Famicef (BD);</li>\n      <li>Farmacef (TH);</li>\n      <li>Fornax (PE);</li>\n      <li>Froxime (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Furacam (EC);</li>\n      <li>Furobioxin (MX);</li>\n      <li>Furoxim (PH);</li>\n      <li>Furoxime (TH);</li>\n      <li>Glanax (VN);</li>\n      <li>Gomcef (KR);</li>\n      <li>Jectocef (PH);</li>\n      <li>Keef-250 (PH);</li>\n      <li>Kefezy (PH);</li>\n      <li>Kefrox (LK);</li>\n      <li>Kefstar (PH);</li>\n      <li>Kefurox (LU);</li>\n      <li>Ketocef (HR);</li>\n      <li>Kimatsef (UA);</li>\n      <li>Magnaspor (TH);</li>\n      <li>Maxil (JO, QA);</li>\n      <li>Medaxetine (VN);</li>\n      <li>Medxime (PH);</li>\n      <li>Milcef (LK);</li>\n      <li>Neurox-250 (TH);</li>\n      <li>Novador (MX);</li>\n      <li>Novocef (HR);</li>\n      <li>Olcef (KR);</li>\n      <li>Orapen (ZW);</li>\n      <li>Oraxim (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Oxtercid (ID);</li>\n      <li>Profurex (PH);</li>\n      <li>Rucef (PH);</li>\n      <li>Sefuxim (HK);</li>\n      <li>Sharox-500 (ID);</li>\n      <li>Shincef (KR);</li>\n      <li>Situroxime (ID);</li>\n      <li>Teikeden (HK);</li>\n      <li>Unoximed (PH);</li>\n      <li>Vekfazolin (GR);</li>\n      <li>Vexuro (LK);</li>\n      <li>Xorim (LB, QA);</li>\n      <li>Xorimax (HK, LB, MY, PH, QA, SG);</li>\n      <li>Xorufec (MX);</li>\n      <li>Yokel (UA);</li>\n      <li>Zamur (CR, DO, GT, HN, NI, PA, QA, SV, TT);</li>\n      <li>Zegen (PH);</li>\n      <li>Zenon (QA);</li>\n      <li>Zetnil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Zilisten (MT);</li>\n      <li>Zinacef (AE, BB, BE, BG, BH, CH, CN, CO, CY, CZ, DK, EE, ES, ET, FI, GB, GR, HU, IE, IS, JO, KW, LB, LK, LT, LU, MT, NL, NO, NZ, PH, PL, PT, QA, RU, SA, SE, SK, TR, VN, ZW);</li>\n      <li>Zinat (CH);</li>\n      <li>Zincef (KR);</li>\n      <li>Zinnat (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PY, QA, RO, SA, SC, SD, SG, SK, SL, SN, SR, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Zocef (TH, TZ);</li>\n      <li>Zoref (PT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, &quot;Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months,&quot; <i>Pediatrics</i>, 2011, 128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ceftin (cefuroxime) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefuroxime [prescribing information]. Eatontown, NJ: West-Ward Pharmaceutical Corp; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Louvois J, Mulhall A, and Hurley R, &ldquo;Cefuroxime in the Treatment of Neonates,&rdquo; <i>Arch Dis Child</i>, 1982, 57(1):59-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/7065695 /pubmed\" target=\"_blank\" id=\"7065695 \">7065695 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. December 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al, &quot;The Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson JD, &ldquo;Cefuroxime: A Cephalosporin With Unique Applicability to Pediatric Practice,&rdquo; <i>Pediatr Infect Dis</i>, 1983, 2(5):394-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/ 6356062 /pubmed\" target=\"_blank\" id=\" 6356062 \"> 6356062 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson DC, Cookson TL, Grisafe JA. Concentration guidelines for parenteral antibiotics in fluid-restricted patients. <i>Drug Intell Clin Pharm</i>. 1987;21(12):985-989.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/3428165 /pubmed\" target=\"_blank\" id=\"3428165 \">3428165 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-pediatric-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13137 Version 200.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F148304\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F148305\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046145\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442230\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046138\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F148279\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F148263\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046149\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F5193891\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046148\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F148361\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F148358\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F148286\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F148267\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298999\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F148272\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F148300\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F148275\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5193889\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046144\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F148266\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F148285\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F148288\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F148291\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13137|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefuroxime-drug-information\" class=\"drug drug_general\">Cefuroxime: Drug information</a></li><li><a href=\"topic.htm?path=cefuroxime-patient-drug-information\" class=\"drug drug_patient\">Cefuroxime: Patient drug information</a></li></ul></div></div>","javascript":null}